Laurel Habel to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Laurel Habel has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
1.417
-
Statins and Reduced Risk of Liver Cancer: Evidence for Confounding. J Natl Cancer Inst. 2016 10; 108(10).
Score: 0.474
-
Erratum: Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients. Pharmacoepidemiol Drug Saf. 2008 Jul; 17(7):751.
Score: 0.272
-
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008 Jan; 17(1):27-36.
Score: 0.263
-
Statin use and risk of multiple myeloma: An analysis from the cancer research network. Int J Cancer. 2017 08 01; 141(3):480-487.
Score: 0.126
-
Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2479-87.
Score: 0.079
-
Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study. Drugs. 2009 Jul 30; 69(11):1445-57.
Score: 0.073
-
Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2007 Nov; 16(11):2218-25.
Score: 0.065
-
Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 2008 Jun; 109(3):573-9.
Score: 0.064